stoxline Quote Chart Rank Option Currency Glossary
Cue Biopharma, Inc. (CUE)
1.59  0.01 (0.63%)    05-30 15:45
Open: 1.6
High: 1.6587
Volume: 112,133
Pre. Close: 1.58
Low: 1.55
Market Cap: 77(M)
Technical analysis
2024-05-30 3:13:41 PM
Short term     
Mid term     
Targets 6-month :  2.21 1-year :  2.63
Resists First :  1.89 Second :  2.25
Pivot price 1.71
Supports First :  1.3 Second :  1.08
MAs MA(5) :  1.63 MA(20) :  1.79
MA(100) :  2.07 MA(250) :  2.59
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13 D(3) :  14.3
RSI RSI(14): 43.9
52-week High :  4.88 Low :  1.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CUE ] has closed above bottom band by 27.3%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.67 - 1.68 1.68 - 1.69
Low: 1.54 - 1.56 1.56 - 1.57
Close: 1.56 - 1.58 1.58 - 1.6
Company Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 09 May 2024
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance

Wed, 08 May 2024
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit - GlobeNewswire

Thu, 25 Apr 2024
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks - Yahoo Finance

Wed, 24 Apr 2024
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

Tue, 16 Apr 2024
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money - Simply Wall St

Mon, 08 Apr 2024
Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 49 (M)
Shares Float 45 (M)
Held by Insiders 0.6 (%)
Held by Institutions 33.6 (%)
Shares Short 4,960 (K)
Shares Short P.Month 4,200 (K)
Stock Financials
EPS -1.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.62
Profit Margin 0 %
Operating Margin -737.8 %
Return on Assets (ttm) -47.3 %
Return on Equity (ttm) -117.5 %
Qtrly Rev. Growth 818.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.14
EBITDA (p.s.) -1.05
Qtrly Earnings Growth 0 %
Operating Cash Flow -39 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -1.46
PEG Ratio 0
Price to Book value 2.59
Price to Sales 11.15
Price to Cash Flow -2.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android